PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
Recruiting · NCT06673017 · Interventional (participants receive a specific treatment) · Lead sponsor: PanTher Therapeutics
View the official record on ClinicalTrials.gov →Interventions studied
PTM-101
What this trial is about
This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Imaging consistent with primary borderline resectable or locally advanced PDAC. PDAC may be confirmed by histology/cytology either at study-mandated laparoscopy or by prior biopsy/cytology
- Indicated for laparoscopy
- No prior therapy of any kind for PDAC
- Acceptable laboratory values
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2
- Ability to provide informed consent
- No symptomatic pancreatitis
- No other active medical issues which would confound interpretation of safety monitoring, efficacy results or prevent the subject from study participation
- Subjects with childbearing potential must agree to use adequate contraception throughout study participation
Exclusion criteria
- Active non-pancreatic cancer that currently requires treatment or is being treated; diagnosis of another malignancy within the past 2 years. This criterion excludes a history of carcinoma in situ of the cervix, superficial non-melanoma skin cancers, or superficial bladder cancer that has been adequately treated, or stage 1 prostate cancer that does not require treatment or requires only treatment with luteinizing hormone-releasing hormone agonists or antagonists if initiated at least 30 days prior to screening). Other potentially indolent cancers may be considered.
- Contraindications or allergies to paclitaxel, PLGA (poly(lactic-co-glycolic ) acid), or contraindications to implantation of PTM-101 or chemotherapies in protocol (e.g., FOLFIRINOX, gemcitabine, nab-paclitaxel)
- Known history of human immunodeficiency virus (HIV) or active viral hepatitis
- Active ongoing infection or autoimmune disease which may preclude laparoscopy, placement of PTM-101, administration of chemotherapy or surgical resection of pancreatic tumor
- Inability to comply with activities and therapeutic interventions as outlined in the schedule of events
- Currently enrolled in another investigational drug or device trial
- Women who are pregnant or breastfeeding or who plan to become pregnant or breastfeed; men who plan to donate sperm or conceive a child
- Any other medical or surgical conditions, including prior abdominal surgery, that would preclude safe laparoscopy or implantation in the opinion of the investigator
Where it is running
8 locations listed across 6 US states.
- Hoag Memorial Hospital Presbyterian - Newport Beach, California, United States
- University of Miami Sylvester Cancer Center - Miami, Florida, United States
- Karmanos Cancer Institute - Detroit, Michigan, United States
- Northwell Health Zuckerberg Cancer Center - Lake Success, New York, United States
- University of Texas Southwestern Medical Center - Dallas, Texas, United States
- The University of Texas MD Anderson Cancer Center - Houston, Texas, United States
- Virginia Mason Medical Center - Seattle, Washington, United States
- The Alfred - Melbourne, Victoria, Australia